CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Allarity Therapeutics A/S is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Allarity Therapeutics A/S
Venlighedsvej 1
HOERSHOLM, 2970  Denmark
This company is no longer actively traded on any major stock exchange.
Business Summary
Allarity Therapeutics A/S, formerly known as ONCOLOGY VENTURE A/S, is a Danmark-based company engaged in the development of anticancer medicines. The Company s current priority program focus is on the advancement of three precision medicine treatments: 2X-121, Dovitinib and Ixempra targeting the market for the treatment of ovarian cancer, breast cancer, and renal cell carcinoma.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202112/31/2020Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board DuncanMoore 62 12/1/2018 12/1/2018
CEO Peter B.Jensen
COO Ulla H.Buhl
12 additional Officers and Directors records available in full report.

Business Names
Business Name
2X Oncology Inc.
ALLR
ALLRBTU
5 additional Business Names available in full report.

General Information
Number of Employees: 14 (As of 12/31/2020)
Outstanding Shares: 403,791,200 (As of 9/30/2021)
Shareholders: 7,180
Stock Exchange: STO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 5, 2024